Around the Region

Alnylam acquires a Merck unit

Alnylam Pharmaceuticals Inc., a Cambridge company specializing in RNA interference therapies designed to silence genes that cause diseases, said it has acquired a Merck subsidiary called Sirna Therapeutics, which also works on RNA technologies, for $175 million.

The acquisition of Merck’s RNAi intellectual property will advance Alnylam’s plans to develop a new class of medicines, Alnylam said.


Under the agreement, Alnylam will make an upfront payment of $25 million in cash and $150 million in common stock to Merck.

Merck is also eligible to receive up to $105 million in developmental and sales milestone payments per product, as well as single-digit royalties, associated with the progress of certain pre-clinical candidates discovered by Merck.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

Merck is also eligible to receive up to $10 million in milestone payments and single-digit royalties on Alnylam products covered by Sirna Therapeutics’ patent estate.

Chris Reidy

Chris Reidy can be reached at
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.